Read how Zai Lab’s zocilurtatug pelitecan posted strong AACR 2026 data in SCLC brain metastases and NECs, and what it could change next.
DualityBio’s trastuzumab pamirtecan has entered China review for HER2-positive breast cancer. Read what this filing could change next.
NEOK002 has cleared the FDA IND stage. Read why this bispecific ADC matters for solid tumors, clinical strategy, and the next phase of ADC competition.
Orum Therapeutics presents ORM-1153 DAC preclinical data at AACR 2026, including primate safety findings ahead of a planned AML IND filing. Read the analysis.
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel […]
EMA begins review of ENHERTU plus pertuzumab for first-line HER2-positive metastatic breast cancer. Find out what this means for frontline therapy options.
AstraZeneca PLC and Daiichi Sankyo’s HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for use in patients with HER2-positive early breast cancer who have residual invasive disease following neoadjuvant treatment and are at high risk of recurrence. The designation is based on positive results […]
Astellas Pharma Inc. and Pfizer Inc. have announced that their antibody-drug conjugate PADCEV (enfortumab vedotin), in combination with the PD-1 inhibitor pembrolizumab (marketed as Keytruda by Merck), met key survival endpoints in the Phase 3 EV-304 trial. In cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC), the combination significantly improved both event-free survival and overall survival […]
Biohaven Ltd. presented updated Phase 1 clinical data on BHV-1510, its next-generation Trop2-targeting antibody-drug conjugate, at the 2025 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress in London. The results, derived from a heavily pretreated population with advanced or metastatic solid tumors, showed encouraging response rates across non-small cell lung cancer, endometrial cancer, and urothelial […]